Publication Name	World Journal of Gastroenterology
Manuscript ID	96149
Country	China

Received	2024-04-28 06:00
Peer-Review Started	2024-04-28 06:00
To Make the First Decision
Return for Revision	2024-05-22 05:51
Revised	2024-05-30 14:03
Second Decision	2024-06-21 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-21 05:10
Articles in Press	2024-06-21 05:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-02 01:00
Publish the Manuscript Online	2024-07-09 14:00

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients
Manuscript Source	Unsolicited Manuscript
All Author List	Li-Yang Meng, Chao-Ting Yang, Jian-Feng Bao and Jin-Song Huang
ORCID	Author(s) ORCID Number Jin-Song Huang http://orcid.org/0000-0003-1254-1181
Funding Agency and Grant Number	Funding Agency Grant Number Biomedical Enterprise Project of Hangzhou Science and Technology Bureau 2021WJCY061, 2022WJC230
Corresponding Author	Jin-Song Huang, Doctor, Chief Doctor, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, No. 2 Hengbu Road, Hangzhou 310023, Zhejiang Province, China. huangjinsongyz@126.com
Key Words	Tenofovir amibufenamide; Chronic hepatitis B; Non-alcoholic fatty liver disease; Alanine transaminase normalization; Virological response
Core Tip	It is well known that every chronic hepatitis B (CHB) patient should receive antiviral therapy. Although nucleos(t)ide analogs are still the first choice for CHB treatment, they are associated with many side effects, such as renal damage, osteoporosis, and lipid metabolism disorders. Therefore, as a new antiviral drug in China, tenofovir amibufenamide (TMF) is as effective as tenofovir alafenamide (TAF) in treating CHB and has comparable safety profiles, which suggests that TMF may be a viable alternative to TAF for CHB treatment.
Publish Date	2024-07-09 14:00
Citation	<p>Meng LY, Yang CT, Bao JF, Huang JS. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. <i>World J Gastroenterol</i> 2024; 30(26): 3261-3263</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i26/3261.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i26.3261

Full Article (PDF)	WJG-30-3261-with-cover.pdf
Manuscript File	96149_Auto_Edited-YJP.docx
Answering Reviewers	96149-answering-reviewers.pdf
Audio Core Tip	96149-audio.mp3
Conflict-of-Interest Disclosure Form	96149-conflict-of-interest-statement.pdf
Copyright License Agreement	96149-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	96149-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	96149-non-native-speakers.pdf
Peer-review Report	96149-peer-reviews.pdf
Scientific Misconduct Check	96149-scientific-misconduct-check.png
Scientific Editor Work List	96149-scientific-editor-work-list.pdf
CrossCheck Report	96149-crosscheck-report.pdf